[1] Zhou X, Liu K, Shi C, et al. Estimation of the spatial pattern of gout prevalence across China by wastewater-based epidemiology[J]. Sci Total Environ, 2024, 924: 171565. doi: 10.1007/s11926-014-0492-x. [2] Schlesinger N, Thiele RG. The pathogenesis of bone erosions in gouty arthritis[J]. Ann Rheum Dis, 2010, 69: 1907-1912. [3] McQueen FM, Chhana A, Dalbeth N. Mechanisms of joint damage in gout: evidence from cellular and imaging studies[J]. Nat Rev Rheumatol, 2012, 8: 173-181. [4] Miossec P. Local and systemic effects of IL-17 in joint inflammation: a historical perspective from discovery to targeting[J]. Cell Mol Immunol, 2021, 18: 860-865. [5] 韩欣欣. 痛风性关节炎临床及发病机制研究[D]. 北京: 北京协和医学院, 2021: 38-101. [6] 白煜佳. 痛风性关节炎患者血清及组织中Il-17水平研究[D]. 北京: 北京协和医学院, 2015: 44-60. [7] 狄虹. IL-17参与痛风性关节炎发病机制研究及相关药物初探 [D]. 北京: 北京协和医学院, 2024: 29-60. [8] Chhana A, Dalbeth N. The gouty tophus: a review[J]. Curr Rheumatol Rep, 2015, 17: 19. doi: 10.1007/s11926-014-0492-x. [9] Yan C, Shi Y, Yuan L, et al. Mitochondrial quality control and its role in osteoporosis[J]. Front Endocrinol, 2023, 14: 1077058. doi: 10.1007/s11926-014-0492-x. [10] Neogi T, Jansen T L, Dalbeth N, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative[J]. Ann Rheum Dis, 2015, 74: 1789-1798. [11] Dalbeth N, Smith T, Nicolson B, et al. Enhanced osteoclastogenesis in patients with tophaceous gout: urate crystals promote osteoclast development through interactions with stromal cells[J]. Arthritis Rheum, 2008, 58: 1854-1865. [12] Tsukasaki M, Takayanagi H. Osteoimmunology: evolving concepts in bone-immune interactions in health and disease[J]. Nat Rev Immunol, 2019, 19: 626-642. [13] Zeng Z, Zhou X, Wang Y, et al. Mitophagy-A new target of bone disease[J]. Biomolecules, 2022, 12:1420. doi: 10.3390/biom12101420. [14] Jang J S, Hong S J, Mo S, et al. PINK1 restrains periodontitis-induced bone loss by preventing osteoclast mitophagy impairment[J]. Redox Biol, 2024, 69: 103023. doi: 10.1016/j.redox.2023.103023. [15] Liao H, Chang X, Gao L, et al. IL-17A promotes tumorigenesis and upregulates PD-L1 expression in non-small cell lung cancer[J]. J Transl Med, 2023, 21: 828. doi: 10.1186/s12967-023-04365-3. |